Immuno-Oncology | Specialty

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

January 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

January 21st 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Frontline Immunotherapy Combo Setbacks Strike NSCLC

January 21st 2017

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

PD-1/VEGF Combos a Next Step for RCC Treatment

January 20th 2017

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

Pembrolizumab/Ramucirumab Combo Active in Gastric Cancers

January 20th 2017

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer

January 20th 2017

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

January 20th 2017

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

Dr. Agarwal on Toxicities With Checkpoint Inhibitors in RCC

January 20th 2017

Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

January 20th 2017

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Dr. Herbst on Combination Therapies for Lung Cancer

January 20th 2017

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Dr. Bunn on Combining Immunotherapy and Chemotherapy in Lung Cancer

January 19th 2017

Paul A. Bunn, Jr., MD, professor of Medicine, head of the Division of Medical Oncology at the University of Colorado, discusses combining immunotherapy with chemotherapy and targeted agents in lung cancer.

Dr. Horwitz on Ongoing Trials in T-Cell Lymphoma

January 19th 2017

Steven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.

Dr. Motzer on Nivolumab Versus Everolimus in Renal Call Carcinoma

January 18th 2017

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Hodgkin Lymphoma Field Evolving With Immunotherapy, Adjustments to Standard Approaches

January 18th 2017

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.

Researcher Discusses Optimal Sequencing in Advanced RCC

January 16th 2017

Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.

Dr. McDermott on VEGF Plus PD-1 in Renal Cell Carcinoma

January 14th 2017

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

Dr. Dadu on Immunotherapy in Thyroid Cancer

January 14th 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy to treat patients with thyroid cancer.

Big Hopes for Big Data: Digital Information Focus Underpins Cancer Moonshot Goals

January 13th 2017

The ambitious goals of the Cancer Moonshot initiative, now incorporated into the recently enacted 21st Century Cures Act, are generating excitement among oncology leaders.

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Efforts Continue to Expand Immunotherapy Impact in Sarcoma

January 12th 2017

Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.